In cancer, the interaction between the PD-L1 ligand expressed on malignant tumor cells and the PD-1 receptor located on cytotoxic T lymphocytes (CD8+) suppresses the antitumor activity of these immune cells and promotes cancer immune evasion. This evidence concerns the gene CD8A and cancer.